# Orforglipron UK: Eli Lilly’s Oral Weight Loss Tablet — Latest Update
When Wegovy tablets received MHRA approval on 11 June 2026, they became the first oral GLP-1 medicine licensed for weight management in the UK. But they are unlikely to be the last. Eli Lilly — the maker of Mounjaro — is developing its own oral GLP-1 tablet, orforglipron, which could seek UK regulatory approval as early as 2027.
For people deciding whether to start oral Wegovy now or wait to see what else becomes available, understanding what orforglipron is — and what it is not — matters. Here is the latest.
> Wegovy tablets are a prescription-only medicine. Always consult a qualified healthcare professional before starting or changing treatment.
—
## What is orforglipron?
Orforglipron is a once-daily oral GLP-1 receptor agonist in development by Eli Lilly. Like semaglutide, it activates the GLP-1 receptor — the same pathway that reduces appetite, slows gastric emptying, and supports weight loss. Unlike semaglutide, however, orforglipron is a small-molecule drug rather than a peptide. This distinction has one significant practical implication for patients: orforglipron does not require the strict fasting protocol that oral semaglutide demands.
Wegovy tablets (oral semaglutide) must be taken on an empty stomach, at least 30 minutes before food or any drink other than plain water. For many people, building this fasting window into a morning routine is manageable — but it is a real lifestyle requirement. Orforglipron, being a small molecule, is absorbed differently and does not require fasting before or after dosing. This could make it significantly easier to take for a proportion of patients.
—
## What do the Phase 3 results show?
Orforglipron has completed Phase 3 trials. The ATTAIN programme — Eli Lilly’s Phase 3 clinical trial series for orforglipron in obesity — reported results in late 2025. The headline findings showed meaningful weight loss comparable to existing GLP-1 treatments, with the convenience advantage of no fasting requirement.
In the ATTAIN-1 trial, participants taking orforglipron at the highest studied dose achieved approximately 9–10% average body weight reduction over 36 weeks. Extended follow-up data and longer-duration results are consistent with this trajectory. The trial design and population differ from the OASIS 2 semaglutide trial, so a direct numerical comparison is not straightforward — different trial lengths, different patient populations, and different dose escalation schedules make headline figures difficult to place side by side without careful interpretation.
What the Phase 3 data does clearly show is that orforglipron produces clinically meaningful weight loss, is well-tolerated, and avoids the fasting requirement that some patients find burdensome. The gastrointestinal side effect profile — nausea, vomiting, diarrhoea — appears broadly similar to other GLP-1 medicines.
—
## When might orforglipron be available in the UK?
Eli Lilly has not announced an official submission timeline to the MHRA, but regulatory analysts expect an application in late 2026, with a decision possible in 2027. Regulatory review by the MHRA typically takes 150–210 days from a valid application. If the timeline holds, UK patients could have access to orforglipron as a licensed medicine from 2027.
NHS funding would require a subsequent NICE evaluation — likely to take an additional 12–18 months after approval. Private prescription access would be available from approval date, assuming commercial supply is established.
—
## How does orforglipron compare to Wegovy tablets available now?
The two medicines are in the same class and work through the same receptor. The practical differences for a patient considering their options right now are:
**Fasting requirement:** Wegovy tablets require 30 minutes of fasting after taking (water only, maximum 120ml). Orforglipron does not. This is a meaningful quality-of-life difference for people with early morning work schedules, families to manage, or conditions such as reflux that make early-morning routines complicated.
**Availability:** Wegovy tablets are available now via private prescription in the UK, with seven providers taking pre-orders at prices from £64/month. Orforglipron is not yet approved in the UK and is not available by any legal route.
**Weight loss evidence:** Both medicines produce clinically meaningful weight loss. Oral semaglutide at 25mg has shown an average of 15.1% body weight reduction over 68 weeks (OASIS 2). Orforglipron’s trial data at 36 weeks shows approximately 9–10% — but the trial durations are different, making this a comparison that requires caution. Longer follow-up data for orforglipron continues to accumulate.
**Dose schedule:** Wegovy tablets escalate from 1.5mg to 25mg over approximately six months. Orforglipron has its own escalation schedule that differs from semaglutide’s.
—
## Should you wait for orforglipron?
This depends on your circumstances. If the fasting requirement of Wegovy tablets is genuinely a barrier for you, and you are not in urgent need of treatment, waiting to understand orforglipron’s availability and pricing in the UK is a reasonable position. If, on the other hand, oral Wegovy is appropriate for your situation and you are ready to start now, a wait of at least 12–18 months before orforglipron becomes available on private prescription in the UK is likely.
The decision should be made in conversation with your prescriber, who can weigh your individual health needs and the currently available evidence.
—
## We track the oral GLP-1 landscape
CompareWegovyPrices.co.uk monitors not just Wegovy tablet prices, but the broader UK oral GLP-1 market — including Rybelsus (oral semaglutide licensed for type 2 diabetes, not weight loss), orforglipron developments, and any new entrants.
[Compare Wegovy tablet prices now →](/providers/) or [sign up for alerts](/providers/) to be notified when the market changes.
—
*This article is for informational purposes only and does not constitute medical advice. Wegovy tablets are a prescription-only medicine. Orforglipron is not currently approved in the UK. Always consult a registered healthcare professional before making treatment decisions. CompareWegovyPrices.co.uk is not affiliated with Eli Lilly or Novo Nordisk.*
